Herantis Pharma Plc Provides Update on Timeline for Ongoing Phase 1-2 CDNF Trial
Herantis Pharma Plc Provides Update on Timeline for Ongoing Phase 1-2 CDNF Trial Herantis Pharma PlcCompany release 26 September 2019 at 9:00 AM Herantis Pharma Plc (“Herantis” or “Company”) announced today an update on the timeline for the ongoing Phase 1-2 clinical trial examining Herantis’ proprietary neuroprotective factor and novel drug candidate, CDNF, in patients with Parkinson’s disease. Patient recruitment has been completed and the medical device used in injecting CDNF has been implanted in 17 patients. The trial continues to proceed as anticipated and its first phase is